Feb 27, 2019 / 01:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Adaptimmune Therapeutics conference call. (Operator Instructions)
I would now like to introduce your host for today's conference, Juli Miller. You may begin.
Juli P. Miller - Adaptimmune Therapeutics plc - Director of IR
Good morning, and welcome to Adaptimmune's conference call to discuss our fourth quarter and full year 2018 financial results and other business updates. We issued a press release earlier this morning, and I would ask you to please review the full text of our forward-looking statements. As a reminder, we anticipate making projections during this call, and actual results could differ materially due to a number of factors.
In addition, I would like to make you aware of an update to our SPEAR T-cell nomenclature. From here forward, we will refer to our SPEAR T-cell's with a prefix, ADP for our company name, followed by a reference to the HLA-type specific for the SPEAR T-cell, which is currently A2 for all of our trials and then a reference to the target antigen.
So
Q4 2018 Adaptimmune Therapeutics PLC Earnings Call Transcript
Feb 27, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers